| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2317 | Gr134056x | Negative control for GI181771X |
|
| DCC2318 | gr-205171 Dihydrochloride | Selective and brain penetrant NK1-receptor antagonist |
|
| DCC2319 | Gr269666a | Novel inhibitor of the EGFr and C-erbB-2. |
|
| DCC2320 | Gr-55562 Dihydrobromide | 5-HT1B/5-HT1D serotonin receptor antagonist |
|
| DCC2321 | Gr-65630 | 5-HT3 receptor antagonist |
|
| DCC2322 | Gramibactin | Bacterial siderophore with a diazeniumdiolate ligand system |
|
| DCC2323 | Granisetron | Potent 5HT3 antagonist |
|
| DCC2324 | Grassypeptolide A | Novel Nrf2 modulator via a thus far uncharacterized mechanism |
|
| DCC2325 | Grayanotoxin Iii | Natural blocker of the voltage-gated sodium channels located in the cell membrane of neurons |
|
| DCC2326 | Grc-17536 | Novel orally available, potent and selective inhibitor of Transient Receptor Potential Ankyrin 1 (TRPA1) with IC50 value less than 10 nM |
|
| DCC2327 | Grc-6211 | Novel oral specific TRPV1 antagonist, decreasing bladder overactivity and noxious bladder input in cystitis animal models |
|
| DCC2328 | Grincamycin B | Natural Potent Inhibitor for Glioblastoma Stem Cell via Targeting RHOA and PI3K/AKT |
|
| DCC2329 | Grk5-in-2 | Novel potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor |
|
| DCC2330 | Grk6-in-18 | Novel, potent, and selective G protein-coupled receptor kinase 6 (GRK6) inhibitor with an IC50 value of 6 nM against GRK6 and selectivity against a panel of 85 kinases |
|
| DCC2331 | Grl-117c | Novel CCR5 inhibitor, inhibiting the replication of wild-type R5-HIV-1 |
|
| DCC2332 | Grl-8234 | Novel β-Secretase BACE1 Inhibitor, reversing memory impairments and rescuing age-related cognitive decline |
|
| DCC2333 | Grp-156784 | Novel allosteric inhibitor of respiratory syncytial virus (RSV) |
|
| DCC2334 | Gs-441524 Triphosphate (gs-443902 Sodium) | Novel potent inhibitor of feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies |
|
| DCC2335 | Gs-563253 | Novel Inhibitor of Hepatitis C Viral Infectivity |
|
| DCC2336 | Gs-621763 | Novel oral prodrug of GS-441524, inhibiting SARS-CoV-2, including variants of concern (VOC) in cell culture and human airway epithelium organoids |
|
| DCC2337 | Gs-8374 | Potent and selective inhibitor of HIV-1 protease, effectively inhibiting protease mutants with amino acid insertions, also inhibiting major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease |
|
| DCC2338 | Gsa-0902 | Novel high potent and selective stabilizer of the MYC G-quadruplex (G4) |
|
| DCC2339 | gsh-mem | Glutamate receptor antagonist and radical scavenging agent |
|
| DCC2340 | Gsk002 | Novel allosteric HIV-1 integrase (IN) inhibitor, disrupting formation of mature HIV particles |
|
| DCC2341 | Gsk059a | Novel potent EchA6 inhibitor |
|
| DCC2342 | Gsk1000163a | Potent inhibitor of AKT kinase |
|
| DCC2343 | Gsk-1004723 | Novel dual H1 and H3 receptor antagonist with a long duration of action |
|
| DCC2344 | Gsk1007102b Tfa Salt | Potent inhibitor of AKT kinase, showing activity against auxotrophic M. tuberculosis and being potentiated with meropenem |
|
| DCC2345 | Gsk1023156a | Novel inhibitor of polo-like kinase |
|
| DCC2346 | Gsk1030058a | Novel inhibitor of polo-like kinase |
|
